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ate changes in categorical and continuous variables, respectively.
RESULTS: Total of 102 patients who were followed up for 3
months are included in this analysis. Of which, 43.1% were
male, mean age was 38.5  12.6 years old, and mean time since
diagnosis was 8.9  8.4 years. The ﬁrst reasons for initiating
RLAI were insufﬁcient response to previous medication (43.1%)
and need for maintenance (24.5%). At 3-months, 98% of
patients were still on RLAI treatment. Comparing the ﬁrst
3-month treatment of RLAI to the 3-month period prior to the
initiation of RLAI for the 102 patients, signiﬁcant decreases were
observed in the proportion of patients hospitalized (26.5% vs.
2.9%, p < 0.001) and the mean number of days in hospital (10.2
days vs. 1.3 days, p < 0.001). By 3-months, there were signiﬁcant
improvements in disease severity and patient functioning; the
average CGI-S score signiﬁcantly decreased from 3.74 at baseline
to 3.33 at 3 months (p < 0.001) and the mean GAF score
signiﬁcantly increased from 51.5 at baseline to 56.0 at 3 months
(p < 0.001). CONCLUSIONS: Based on the 3-month interim
results, treatment with RLAI was associated with reductions in
hospitalizations and improvements in disease severity and patient
functioning in Russian patients with schizophrenia.
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OBJECTIVES: Atypical antipsychotics are widely used in the
pharmacologic management of schizophrenia. A meta-analysis of
oral atypical antipsychotics was conducted to assess the relative
effectiveness of a newly introduced agent, paliperidone extended-
release (ER). METHODS: Randomized placebo-controlled
studies of risperidone, olanzapine, quetiapine and aripiprazole
were identiﬁed via a database search (MEDLINE, Embase, the
Cochrane Library, PsycInfo and the Cumulative Index to Nursing
& Allied Health Literature). Baseline demographic, efﬁcacy and
safety data were extracted and combined in the meta-analysis
using the DerSimonian and Laird approach [1]. Random effects
meta-regression1 was used to assess potential confounding by
patient mean age, gender ratio and duration of therapy on vari-
ability in efﬁcacy and safety. RESULTS: Atypical antipsychotics
as a group had lower odds of withdrawal for any reason than
placebo treatment (OR 0.52, 95%CI 0.46, 0.58), with paliperi-
done ER having lower odds than the antipsychotic class as a
whole (OR 0.43, 95%CI 0.34, 0.53). Odds of withdrawal due to
adverse events were lower with paliperidone ER (OR 0.88,
95%CI 0.71, 1.15) than with risperidone (OR 2.09, 95%CI
0.80, 5.41) and with the atypical antipsychotics as a class (OR
1.02, 95%CI 0.83, 1.25). Paliperidone ER was associated with a
lower odds of somnolence (OR 1.33, 95%CI 0.92, 1.94) than the
atypical class (OR 1.70, 95%CI 1.39, 2.09) and a lower odds of
weight gain (OR 1.75, 95%CI 1.29, 2.37) than all of the atypical
antipsychotics, including risperidone (OR 3.08, 95%CI 1.53,
6.20). The predominant factor in the observed variability in
efﬁcacy was the speciﬁc antipsychotic, rather than patient-related
factors or duration of therapy. CONCLUSIONS: Within the
spectrum of efﬁcacy and safety of the class, Paliperidone ER
demonstrates a unique efﬁcacy and tolerability proﬁle. Owing to
the heterogeneity within the class, information on individual
beneﬁt/risk proﬁles of atypical antipsychotics is necessary for
selecting a speciﬁc treatment for each patient. [1] DerSimonian
R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986;7:177–88.
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OBJECTIVES: Serotonin is critical for maintaining platelet hae-
mostatic function such as aggregation. SSRI-induced upper
gastrointestinal hemorrhage (UGIH) may occur through SSRI-
induced inhibition of serotonin reuptake by platelets, leading to
depletion of serotonin after several weeks of antidepressant (i.e.
SSRI) treatment. The risk of SSRI-induced-UGIH has not been
documented in a U.S. managed care population. The purpose of
this study was to compare the incremental likelihood of UGIH
events with use of SSRIs and in combination with NSAIDs in a
managed care population. METHODS: A retrospective study
was designed using data from a large managed care claims data-
base. Subjects were identiﬁed anytime between October 1, 2005
to September 30, 2006 (index-period) and classiﬁed into SSRI-
users, NSAID-users or SSRI-NSAID concomitant users. Each
subject was matched to a control (non-SSRI/NSAID-user) based
on their index date. All subjects were treatment naïve 12 months
prior to their pre-index period and followed for 12 months post
index date to determine the risk of any UGIH event based on
ICD-9-CM code. RESULTS: A total of 87,054, 275,476, 27,696,
and 386,248 subjects were identiﬁed as SSRI-users, NSAID-
users, concomitant-users and controls at index-period. The
control group was signiﬁcantly (p < 0.001) younger than the drug
cohorts (31vs. 42years), lower (p < 0.001) proportions of females
(47% vs. 57%), and lower (p < 0.001) burden of comorbid
illness as measured by Charlson Comorbidity Index (0.15 vs.
0.50). Compared to the controls, concomitant-users had 1.0%
(OR = 3.32; 95%CI = 2.90–3.79), SSRI-users had 0.8% (RR =
2.59; 95%CI = 2.36–2.86), and NSAID-users had 0.5% (RR =
1.83; 95%CI = 1.69–1.97) cases with a diagnoses of UGIH.
CONCLUSIONS: Current SSRIs that are recommended as ﬁrst
line therapy for depression is associated with a risk of UGIH
within ﬁrst 12-months either alone or in combination with
NSAIDs. Future research needs to estimate the economic burden
of such bleeding events to managed care.
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OBJECTIVES: To determine the epidemiological, clinical, and
economic burden of bipolar disorder (BD) in Europe.
METHODS: A systematic review of publications from the last 10
years relating to the burden of bipolar disorder was conducted,
including studies on epidemiology, patient-related issues, and
costs. RESULTS: Data from the UK, Germany, and Italy indi-
cated a prevalence of bipolar disorder of ~1%, and a misdiag-
nosis rate of 70% from Spain. In one study, up to 75% of
patients had at least one DSM-IV comorbidity, commonly
anxiety disorders and substance/alcohol abuse. Attempted
suicide rates varied between 21–54%, with 18% mortality in the
UK. The chronicity of bipolar disorder exerted a profound and
debilitating effect on the patient. Only 30% of German patients
were employed full time at a level matching their qualiﬁcations.
In Italy, 63–67% of patients were unemployed and in Germany,
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